Trial · NCT05080049
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment rate | 90 days | ≥50% of eligible patients will need to be enrolled, but the trial will not be feasible if the inclusion rate is ≤ 25% or less |
| Primary | Adherence to allocation groups | 90 days | A high level of matching of randomization and group allocation should be achieved, with at least 85% of included patients receiving protocol-allocated treatment, but if ≤ 65% patients receive protocol-allocated treatment, the trial is not feasible |
| Primary | Completion of follow-up of included patients | 90 days | ≥ 85% of patients should be followed through to the end of follow-up, but if \<65% patients are followed through to the last visit, the protocol will not be feasible |
| Secondary | The proportion of patients lost to follow-up at each visit | 7, 14, 21, 28 and 90 days | The proportion of patients lost to follow-up at each visit |
| Secondary | The rate of missing data for mortality outcome | 90 days | The rate of missing data for mortality outcome |
| Secondary | The rate of compliance with the therapeutic protocol at each visit for inpatients | 7, 14, 21, and 28 days | The rate of compliance with the therapeutic protocol at each visit for inpatients |
| Secondary | Mean serum hemoglobin value | 28 days | Mean serum hemoglobin value |
| Secondary | ICU mortality | up to 90 days | ICU mortality |
| Secondary | Hospital mortality | up to 90 days | Hospital mortality |
| Secondary | ICU length of stay | up to 90 days | ICU length of stay |
| Secondary | Hospital length of stay | up to 90 days | Hospital length of stay |
| Secondary | Blood transfusion | 90 days | Proportion of patients who received at least one red blood cell transfusion |
| Secondary | number of red blood cells transfused | 90 days | number of red blood cells transfused |
| Secondary | 90 days survival analysis | 90 days | 90 days survival analysis |
| Secondary | Occurrence of hospital readmission (censored at 90 days after inclusion), | 90 days | at least one hospital readmission after the hospital discharge |
| Secondary | Number of days living at home (or previous place of living) | 90 days | Number of days living at home (or previous place of living) at D90 |
| Secondary | Quality of life measured by the EQ-5D 5L scale, EuroQol 5 dimensions | 90 days | The value from this scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine'. The scale is rated from 0 to 100. |
| Secondary | Proportion of patients with a thromboembolic event | 90 days | Thrombolic event: pulmonary embolism, venous or arterial thrombosis |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05080049/registered